| International Ranking of Universities:
McGill Cracks Distinguished Dozen
Friday, November 16, 10:01 am ET
By Neale McDevitt
Source: McGill Reporter
Return
to Homepage | See All
News
Times Higher Ed rankings
|
|
|
In the just-released annual Times Higher-QS World University Rankings, McGill University placed 12th overall—the first time a Canadian university has cracked the top 15 to join Harvard, Oxford, Cambridge, Yale and others among the dozen best universities in the world. The school also ranked ahead of such prestigious US universities as Duke, Stanford, John Hopkins and Cornell. As with last year, Harvard topped the list, with Oxford, Cambridge and Yale tied for second. McGill also had the distinction of being classed as the best public university on the continent. The University of British Columbia (33rd) and the University of Toronto (45th) were the only other two Canadian universities to crack the Top 50.
Since the 2004 inception of the THES annual rankings, McGill has always fared well—the only Canadian university to have made the top 25 every year. While the school's ranking has consistently improved (from 24th in 2005 to 21st in 2006), the nine-place jump this year is significant, especially following the recent launch of Campaign McGill.
"This news is particularly gratifying coming from the Times Higher-QS, which is respected the world over," said McGill Principal and Vice-Chancellor Heather Munroe-Blum. "At a time when universities are generating knowledge and talent for a global marketplace and for a society seeking solutions to increasingly complex problems through research and innovation, this recognition of McGill's role as a world leader is a tribute to the exceptional quality and commitment of our students, faculty and staff."
|
"This news is particularly gratifying coming from the Times Higher-QS, which is respected the world over,"
Heather Munroe-Blum
McGill Principal and Vice-Chancellor |
|
About
McGill University Health Centre:
The
McGill University Health Centre (MUHC), located in
Montreal, Quebec, is one of the most comprehensive
university health centers in North America. The MUHC
represents five teaching hospitals affiliated with
the Faculty of Medicine of McGill University: The
Montreal Children's, Montreal General, Royal Victoria,
and Montreal Neurological hospitals, as well as the
Montreal Chest Institute. The Research Institute of
the MUHC is an internationally recognized biomedical
and healthcare hospital research centre. The Institute
supports over 500 researchers as well as 1,000 graduate
and postdoctoral students. It operates more than 300
laboratories devoted to a broad spectrum of fundamental
and clinical research and it produces over 1,400 publications
per year.
About
Samaritan Therapeutics, Montreal, Canada:
Samaritan
Therapeutics, Inc. is a Canadian company based in
Montreal, Canada, that performs its scientific research
and development in Canada. Samaritan Therapeutics
has a research and development collaboration with
The Research Institute of McGill University Health
Center to develop new and improved innovative drugs
to relieve the suffering of patients with Alzheimer's,
Cancer, Heart disease, and Infectious disease.
Samaritan
Pharmaceuticals: ``Transforming Today's Science Into
Tomorrow's Cures...''
Samaritan Pharmaceuticals is a life science company
focused on commercializing innovative drugs to relieve
the suffering of patients with Alzheimer’s,
Cancer, Heart disease, and Infectious disease.
Website:
http://www.samaritanpharma.com.
Please register so we can notify you of upcoming conference
calls, news and events.
Disclaimer:
The company disclaims any information that is created
by an outside party and endorses only information
that is communicated by its press releases, filings,
and Website. This news release contains forward-looking
statements that reflect management's current beliefs
about the potential for its drug candidates, science,
and technology. However, as with any biopharmaceutical
under development, there are significant risks and
uncertainties in the process of development and regulatory
review. There are no guarantees that products will
prove to be commercially successful. For additional
information about the factors that affect the company's
business, please read the company's latest Form 10-K
filed April 13, 2007. The company undertakes no duty
to update forward-looking statements.
Contact:
The Investor Relations Group
Investor Relations:
Adam Holdsworth
Erica Ruderman
Rachel Colgate
212-825-3210
Samaritan
Pharmaceuticals, Inc.
Kristi Eads
702-735-7001
|
